EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
On Wednesday, Vivani Medical, Inc. (NASDAQ:VANI) reported preclinical liver fat results with its exenatide implant for obese patients.
週三，維瓦尼醫療公司（美國納斯達克證券交易所股票代碼：VANI）報道稱，其埃塞那肽植入物在肥胖患者身上能夠改善肝脂肪臨床試驗結果。
Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under the brand names Byetta and Bydureon BCise to treat type 2 diabetes.
阿斯利康有限公司（納斯達克證券交易所股票代碼：AZN）銷售埃塞那肽的品牌爲Byetta和Bydureon BCise, 用於治療2型糖尿病。
Also Read: EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use.
此外讀者還可閱讀專題報道：維瓦尼醫療公司重點介紹了GLP-1植入物的減重數據，還支持潛在獸醫用途。
"The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant provides further support that the NanoPortal implant technology continues to hold great potential as a highly differentiated treatment option for the treatment of obesity and chronic weight management as well as related metabolic disorders...Our first clinical study, LIBERATE-1, is anticipated to start in the fourth quarter of 2024 with results in 2025," said Adam Mendelsohn, Vivani President and CEO.
維瓦尼醫療公司總裁兼首席執行官亞當·門德爾森表示：「通過我們微型皮下埃塞那肽植入物在臨床前觀察到的肝脂肪減少，進一步證明了NanoPortal植入技術作爲高度差異化的肥胖治療選擇以及相關代謝紊亂的巨大潛力……我們的第一項臨床研究（LIBERATE-1）計劃在2024年第四季度開始，結果將在2025年公佈。」
Vivani's GLP-1 (exenatide) implant produced a sham-implant-adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing.
維瓦尼的GLP-1（埃塞那肽）植入物在一次給藥後預期每年兩次服用，在肥胖小鼠模型中，相較於假植入物，肝脂肪減少82%。
These liver fat data are consistent with published results from similar investigations with semaglutide, the active pharmaceutical ingredient in Novo Nordisk A/S' (NYSE:NVO) Ozempic and Wegovy.
這些肝脂肪數據與諾和諾德（紐交所股票代碼：NVO）的Ozempic和Wegovy中的人類胰高血糖素類似物semaglutide的已發表研究結果一致。
Previously reported results from this study in high-fat diet-induced obese mice demonstrated that Vivani's exenatide implant generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration, comparable to the weight loss observed in the semaglutide active control arm in the study.
此前在高脂飲食誘導的肥胖小鼠中進行的這項研究已經報告的結果表明，維瓦尼的埃塞那肽植入物與假植入物對照組相比，在28天的治療期後，體重減輕約20%，與semaglutide的活性對照組中觀察到的體重減輕相當。
The supratherapeutic doses provided for the exenatide implant (single administration delivering exenatide at ~530 nmol/kg/day) and semaglutide (weekly injections of ~2,700 nmol/kg/week) were selected to maximize the weight-loss potential of both exenatide and semaglutide.
選擇超治療劑量提供埃塞那肽植入物（單次給藥每天達到埃塞那肽約530 nmol/kg）和semaglutide（每週注射約2700 nmol/kg/week）是爲了最大限度發揮埃塞那肽和semaglutide的減重潛力。
In June, the FDA cleared Vivani's Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
6月份，FDA批准了Vivani的新藥申請NPm-119的臨床試驗，爲LIBERATE-1 Phase 1試驗的開始鋪平了道路。
Price Action: At the last check on Tuesday, VANI stock was trading higher by 7.32% at $1.32 premarketay.
價格走勢：截至本週二最近一次檢查，VANI股票在盤前交易中上漲7.32%，達到每股1.32美元。
- Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers.
- 阿片類藥物和解：藥品分銷商麥克森、Cencora和卡地納健康將向醫療保險公司支付30000萬美元。
譯文內容由第三人軟體翻譯。